Pfizer’s Ibrance wins broader FDA role as metastatic breast cancer treatment becomes more complex
The FDA approval brings CDK4/6 inhibition into HR-positive, HER2-positive metastatic breast cancer maintenance, although toxicity, immature survival data and a rapidly changing first-line market could shape adoption.
